menu
    • menu

    Company profile for Genfit

    NEW Drugs in Dev: 5
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two d...
    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. Its most advanced drug candidate, elafibranor.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GenfitFrance Flag
    Country
    Country
    France
    Address
    Address
    Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.genfit.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GENFIT Secures FDA Orphan Drug Designation for NTZ in ACLF
    GENFIT Secures FDA Orphan Drug Designation for NTZ in ACLF

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3252148/0/en/GENFIT-Receives-FDA-Orphan-Drug-Designation-for-NTZ-for-the-treatment-of-ACLF.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Ipsen's Iqirvo Sales Hit $200M; GENFIT Gets $20M Milestone
    Ipsen's Iqirvo Sales Hit $200M; GENFIT Gets $20M Milestone

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237572/0/en/GENFIT-to-receive-US-20M-milestone-after-Ipsen-s-Iqirvo-exceeds-the-US-200M-threshold-in-its-first-full-year-of-net-sales.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    GENFIT: Half-Year Report of Liquidity Contract with Commercial
    GENFIT: Half-Year Report of Liquidity Contract with Commercial

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3218098/0/en/GENFIT-Half-Year-Report-of-Liquidity-Contract-with-Cr%C3%A9dit-Industriel-et-Commercial.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    GENFIT Announces 2026 Financial Calendar
    GENFIT Announces 2026 Financial Calendar

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214797/0/en/GENFIT-Announces-2026-Financial-Calendar.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    GENFIT: Reports Positive Phase 1 Results For ACLF Lead Asset
    GENFIT: Reports Positive Phase 1 Results For ACLF Lead Asset

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213994/0/en/GENFIT-Favorable-Phase-1-Safety-Profile-and-Strong-Anti-Inflammatory-Activity-for-ACLF-Lead-Asset-G1090N.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    GENFIT's GNS561 Shows Antitumor Promise in Combo Therapy
    GENFIT's GNS561 Shows Antitumor Promise in Combo Therapy

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203416/0/en/GENFIT-GNS561-Shows-Promising-Antitumor-Activity-in-Combination-Therapy.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search